Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma.

MLA

Thomas MB, et al. “Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma.” Journal of Clinical Oncology, vol. 27, no. 6, Feb. 2009, pp. 843–50. EBSCOhost, https://doi.org/10.1200/JCO.2008.18.3301.

APA

Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, & Abbruzzese J. (2009). Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 27(6), 843–850. https://doi.org/10.1200/JCO.2008.18.3301

Chicago

Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, and Abbruzzese J. 2009. “Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma.” Journal of Clinical Oncology 27 (6): 843–50. doi:10.1200/JCO.2008.18.3301.